Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
Autore:
Jassem, J; Pienkowski, T; Pluzanska, A; Jelic, S; Gorbunova, V; Mrsic-Krmpotic, Z; Berzins, J; Nagykalnai, T; Wigler, N; Renard, J; Munier, S; Weil, C;
Indirizzi:
Med Univ Gdansk, Dept Oncol & Radiotherapy, PL-80211 Gdansk, Poland Med Univ Gdansk Gdansk Poland PL-80211 otherapy, PL-80211 Gdansk, Poland Inst Oncol, Warsaw, Poland Inst Oncol Warsaw PolandInst Oncol, Warsaw, Poland Med Univ Lodz, Lodz, Poland Med Univ Lodz Lodz PolandMed Univ Lodz, Lodz, Poland Inst Oncol & Radiol, Belgrade, Yugoslavia Inst Oncol & Radiol Belgrade Yugoslavia & Radiol, Belgrade, Yugoslavia Oncol Res Ctr, Moscow, Russia Oncol Res Ctr Moscow RussiaOncol Res Ctr, Moscow, Russia Univ Hosp Tumors Zagreb, Zagreb, Croatia Univ Hosp Tumors Zagreb Zagreb Croatia p Tumors Zagreb, Zagreb, Croatia Latvian Canc Ctr, Riga, Latvia Latvian Canc Ctr Riga LatviaLatvian Canc Ctr, Riga, Latvia Uzsoki Hosp, Budapest, Hungary Uzsoki Hosp Budapest HungaryUzsoki Hosp, Budapest, Hungary Ichilov Hosp, IL-64239 Tel Aviv, Israel Ichilov Hosp Tel Aviv Israel IL-64239 ov Hosp, IL-64239 Tel Aviv, Israel Bristol Myers Squibb Co, Waterloo, Belgium Bristol Myers Squibb Co Waterloo Belgium s Squibb Co, Waterloo, Belgium
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 6, volume: 19, anno: 2001,
pagine: 1707 - 1715
SICI:
0732-183X(20010315)19:6<1707:DAPVFD>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; COOPERATIVE-ONCOLOGY-GROUP; CLINICAL SCREENING GROUP; 3-HOUR INFUSION; COMBINATION CHEMOTHERAPY; DOCETAXEL; SURVIVAL; EFFICACY; EORTC; DRUG;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Jassem, J Med Univ Gdansk, Dept Oncol & Radiotherapy, 7 Debomlo St, PL-80211 Gdansk,Poland Med Univ Gdansk 7 Debomlo St Gdansk Poland PL-80211 ansk,Poland
Citazione:
J. Jassem et al., "Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial", J CL ONCOL, 19(6), 2001, pp. 1707-1715

Abstract

Purpose: This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer. Patients and Methods: A total of 267 women with metastatic breast cancer were randomized to receive either AT (doxorubicin 50 mg/m(2) followed 24 hours later by paclitaxel 220 mg/m(2)) or FAC (5-fluorouracil 500 mg/m(2), doxorubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2)), each administered every3 weeks for vp to eight cycles. Patients had to have measurable disease and an Eastern Cooperative Oncology Group performance status of 0 to 2. Only one prior non-anthracycline, nontaxane-containing adjuvant chemotherapy regimen was allowed. Results: Overall response rates for patients randomized to AT and FAC were68% and 55%, respectively (P =.032). Median time to progression and overall survival were significantly longer for AT compared with FAC (time to progression 8.3 months v 6.2 months [P =.034]; overall survival 23.3 months v 18.3 months [P =.13]). Therapy was generally well-tolerated (median of eightcycles delivered in each arm). Grade 3 or 4 neutropenia was more common with AT than with FAC (89% v 65%; P <.001); however, the incidence of fever and infection was low. Grade 3 or 4 arthralgia and myalgia, peripheral neuropathy, and diarrhea were more common with AT, whereas nausea and vomiting were more common with FAC. The incidence of cardiotoxicity was tow in both arms. Conclusion: AT conferred a significant advantage in response rare, time toprogression, and overall survival compared with FAC. Treatment was well-tolerated with no unexpected toxicities, <(c)> 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 19:02:11